{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:20:20Z","timestamp":1788790820987,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1016\/s0306-4530(02)00111-7","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T10:33:19Z","timestamp":1041071599000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S1","title":["Atypical antipsychotics in the EPS-vulnerable patient"],"prefix":"10.1016","volume":"28","author":[{"given":"J.H.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0306-4530(02)00111-7_BIB1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(95)91245-2","article-title":"Risperidone for psychotic and behavioural symptoms in Lewy body dementia","volume":"346","author":"Allen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archinte.1994.00420100093012","article-title":"Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication","volume":"154","author":"Avorn","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB4","first-page":"188","article-title":"Olanzapine as treatment of the neuropsychiatric complications of Parkinson\u2019s disease: an open-label study","volume":"13","author":"Churchyard","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB6","first-page":"595","article-title":"\u2018Seroquel\u2019 (ICI 204,636) treatment of psychosis in parkinsonism (letter)","volume":"11","author":"Evatt","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB7","series-title":"Behavioral Neurology of Movement Disorders, Adv. in Neurology","first-page":"115","article-title":"Parkinson\u2019s disease: drug-induced psychiatric states","author":"Factor","year":"1995"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","article-title":"The emerging role of clozapine in the treatment of movement disorders","volume":"12","author":"Factor","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","article-title":"Quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1531-8257(200005)15:3<579::AID-MDS1024>3.0.CO;2-0","article-title":"Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson\u2019s disease","volume":"344","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199108000-00001","article-title":"The management of the levodopa psychoses","volume":"14","author":"Friedman","year":"1991","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB13","series-title":"Drug-Induced Parkinsonism in Drug-Induced Movement Disorders","author":"Friedman","year":"1992"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1212\/WNL.50.4.1195-a","article-title":"Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease","volume":"50","author":"Friedman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB15","first-page":"285","article-title":"Substituting clozapine for olanzapine in psychiatrically stable Parkinson\u2019s disease patients: results of an open label pilot study","volume":"21","author":"Friedman","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/ajp.139.4.494","article-title":"Pharmacology of hallucinations induced by long-term drug therapy","volume":"139","author":"Goetz","year":"1982","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/S1041610297004213","article-title":"Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience","volume":"9","author":"Goldberg","year":"1997","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp.65.5.774","article-title":"Olanzapine in the treatment of hallucinosis in idiopathic Parkinson\u2019s disease: a cautionary note","volume":"65","author":"Graham","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/S0306-4530(02)00111-7_BIB21","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1176\/jnp.11.3.336","article-title":"Risperidone treatment of behavioral disturbances in outpatients with dementia","volume":"11","author":"Irizarry","year":"1999","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ajp.152.8.1239a","article-title":"Risperidone for treating dementia-associated aggression","volume":"152","author":"Jeanblanc","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB24","series-title":"Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico","article-title":"Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly (poster)","author":"Jeste","year":"1999"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","article-title":"New atypical antipsychotic medications","volume":"32","author":"Jibson","year":"1998","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1212\/WNL.50.4.1183-a","article-title":"Olanzapine can worsen parkinsonism","volume":"50","author":"Jimenez-Jimenez","year":"1998","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/S0306-4530(02)00111-7_BIB27","first-page":"A70","article-title":"Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis","volume":"50","author":"Juncos","year":"1998","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB28","first-page":"A262","article-title":"Quetiapine improves psychotic symptoms associated with Parkinson\u2019s disease","volume":"52","author":"Juncos","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245602","article-title":"Mechanisms of action of atypical antipsychotic drugs: a critical analysis","volume":"124","author":"Kinon","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB31","first-page":"78","article-title":"Risperidone in patient\u2019s with parkinsonism","volume":"13","author":"Leopold","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB32","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.1.7.1441","article-title":"Pharmacology and clinical experience with risperidone","volume":"1","author":"Love","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10401239909147059","article-title":"Experience with the atypical antipsychotics\u2014risperidone and olanzapine in the elderly","volume":"11","author":"Madhusoodanan","year":"1999","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s004060170049","article-title":"Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol","volume":"251","author":"Markianos","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","article-title":"Neuroleptic sensitivity to risperidone in Lewy body dementia","volume":"346","author":"McKeith","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4088\/JCP.v60n0504","article-title":"Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group","volume":"60","author":"McManus","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","article-title":"Risperidone for hallucinations in levodopa-treated Parkinson\u2019s disease patients","volume":"343","author":"Meco","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","article-title":"Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: an open-label, long-term study","volume":"12","author":"Meco","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB40","series-title":"Presented at the Annual Meeting of the American Psychiatric Association, Chicago, Illinois, USA","article-title":"Extrapyramidal symptoms in elderly outpatients treated with either quetiapine or risperidone (poster)","author":"Mintzer","year":"2000"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9","article-title":"Worsening of motor features of parkinsonism with olanzapine","volume":"14","author":"Molho","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11910-001-0085-8","article-title":"Parkinson\u2019s disease: the treatment of drug-induced hallucinations and psychosis","volume":"1","author":"Molho","year":"2001","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","article-title":"Levodopa-induced psychosis: a kindling phenomenon","volume":"135","author":"Moskovitz","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/jnp.10.2.216","article-title":"Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson\u2019s disease","volume":"10","author":"Parsa","year":"1998","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB47","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes","volume":"56","author":"Rich","year":"1995","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 10","key":"10.1016\/S0306-4530(02)00111-7_BIB48","first-page":"5","article-title":"Receptor pharmacology of neuroleptics: relation to clinical effects","volume":"60","author":"Richelson","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1212\/WNL.52.4.782","article-title":"Neurologic side effects in neuroleptic-na\u00efve patients treated with haloperidol or risperidone","volume":"52","author":"Rosebush","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB50","first-page":"819","article-title":"Olanzapine therapy in elderly patients with schizophrenia","volume":"34","author":"Sajatovic","year":"1998","journal-title":"Psychopharmacol. Bull."},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB51","first-page":"274","article-title":"Quetiapine in the treatment of hallucinations in advanced Parkinson\u2019s disease","volume":"13","author":"Samanta","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB52","series-title":"Presented at the American Psychiatric Association Meeting, Washington D.C., USA","article-title":"Effects of Seroquel (quetiapine) on reducing hostility and psychosis in patients with Alzheimer\u2019s disease (poster)","author":"Schneider","year":"1999"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","article-title":"Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine","volume":"235","author":"Scholz","year":"1985","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/070674370004500205","article-title":"Olanzapine use in the elderly: a retrospective analysis","volume":"45","author":"Solomons","year":"2000","journal-title":"Can. J. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB55","first-page":"A215","article-title":"Olanzapine treatment of parkinsonian patients with psychosis","volume":"52","author":"Stover","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-199812020-00004","article-title":"New atypical antipsychotics. Experience and utility in the elderly","volume":"12","author":"Sweet","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB57","first-page":"842","article-title":"Efficacy of Seroquel (quetiapine) in Parkinson\u2019s patients with psychosis","volume":"12","author":"Targum","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004714-200002000-00010","article-title":"Efficacy of quetiapine in Parkinson\u2019s patients with psychosis","volume":"20","author":"Targum","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0149-2918(00)80085-5","article-title":"Long-term use of quetiapine in elderly patients with psychotic disorders","volume":"22","author":"Tariot","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB61","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB62","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"The Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson\u2019s disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB64","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/oxfordjournals.schbul.a033415","article-title":"Tardive dystonia","volume":"25","author":"van Harten","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB65","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.144.9.1148","article-title":"Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study","volume":"144","author":"Weiden","year":"1987","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/S0306-4530(02)00111-7_BIB66","first-page":"62","article-title":"Olanzapine for the treatment of hallucinations\/delusions in Parkinson\u2019s disease","volume":"13","author":"Weiner","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB67","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"Wolters","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB68","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","article-title":"Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease","volume":"47","author":"Wolters","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S0306-4530(02)00111-7_BIB69","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","article-title":"The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease","volume":"9","author":"Workman","year":"1997","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/S0306-4530(02)00111-7_BIB70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4088\/JCP.v58n0705","article-title":"Risperidone in the elderly: a pharmacoepidemiologic study","volume":"58","author":"Zarate","year":"1997","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453002001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453002001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:24:06Z","timestamp":1759681446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453002001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":70,"alternative-id":["S0306453002001117"],"URL":"https:\/\/doi.org\/10.1016\/s0306-4530(02)00111-7","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical antipsychotics in the EPS-vulnerable patient","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0306-4530(02)00111-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Science Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}